Outremont, Canada Clinical Trials

A listing of Outremont, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 928 clinical trials
Featured trial
Parkinson's Progression Markers Initiative Online (PPMI Online)

Parkinson's Progression Markers Initiative Online (PPMI online) is part of the broader Parkinson’s Progression Markers Initiative aimed at better understanding who gets Parkinson’s disease and why. PPMI online is a study collecting participant reported demographic and health information online from people with and without Parkinson’s disease. Once in the study, …

Accepts healthy volunteers
Online studies
UCSF Movement Disorders and Neuromodulation Center (MDNC)
(online study) Contact site
  • 131 views
  • 14 Sep, 2022
  • 1 location
  • Online study
Featured trial
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to assess …

McGill University Health Center Research Institute /ID# 222614
 (2.8 away) Contact site
  • 835 views
  • 10 Aug, 2022
  • +225 other locations
Featured trial
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases …

H pital Maisonneuve-Rosemont /ID# 221925
 (4.8 away) Contact site
  • 380 views
  • 18 Sep, 2022
  • +149 other locations
Featured trial
A Study to Evaluate the Safety Tolerability and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses of BIIB094 administered via intrathecal (IT) injection to participants with Parkinson's Disease (PD). The secondary objective of this study is to evaluate the pharmacokinetic (PK) profile of BIIB094.The study is open for …

dyskinesia
Montreal Neurological Institute and Hospital
 (1.3 away) Contact site
  • 832 views
  • 23 Sep, 2022
  • +15 other locations
Featured trial
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

resting tremor
dopamine
early parkinson's
dopamine transporter
tremor
Montreal Neurological Institute and Hospital
 (1.3 away) Contact site
  • 157 views
  • 27 Sep, 2022
  • +103 other locations
Featured trial
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination …

thioguanine
combination chemotherapy
asparaginase
methotrexate
cytarabine
Chu Sainte-Justine
 (1.2 away) Contact site
  • 5 views
  • 04 Oct, 2022
  • +97 other locations
Featured trial
Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

The purpose of this study is to determine whether FT218 is safe and effective for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy.

somnolence
sleep disorder
stimulant
excessive daytime sleepiness
sodium oxybate
CIUSS de Nord-de-I'ile-de- Montreal- Hopital de Sacre-Coeur de Montreal
 (2.3 away) Contact site
  • 429 views
  • 10 Jul, 2018
  • +52 other locations
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma (InMIND)

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.

rituximab
marginal zone lymphoma
follicular lymphoma
lenalidomide
McGill University Jewish General Hospital
 (1.5 away) Contact site
  • 5 views
  • 21 Sep, 2022
  • +182 other locations
Featured trial
The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis (SCRATCH-AD)

The purpose of the study is to evaluate the effect of ruxolitinib cream on itch in participants with Atopic Dermatitis.

Innovoderm Research
 (2.9 away) Contact site
  • 0 views
  • 04 Oct, 2022
  • 1 location
Featured trial
We are currently recruiting participants for the BLUEPRINT study. This study investigates the effectiveness, safety, and tolerability of the drug BLU-5937 for chronic itch in people with eczema.

The BLUEPRINT study consists of taking two tablets orally, twice a day, for a period of 4 weeks. This treatment is experimental. You will have 50% chance to receive BLU-5937 and 50% chance to receive the placebo. There will be a total of 5 visits at the clinic and 2 …

adult atopic dermatitis
eczema
atopic dermatitis
atopic dermatitis/eczema
dermatitis
Innovaderm Research
 (0.7 away) Contact site
  • 82 views
  • 10 Dec, 2020
  • +24 other locations